Trials / Completed
CompletedNCT03596632
Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers
A Phase 1 Open-label Study Investigating the Excretion Balance, Pharmacokinetics, and Metabolism of a Single Oral Dose of [14C/12C]-Labeled Fenebrutinib in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Male
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the excretion kinetics and mass balance of fenebrutinib in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fenebrutinib | 200-mg (100 µCi) oral solution 14C/12C\]-fenebrutinib |
Timeline
- Start date
- 2018-07-27
- Primary completion
- 2018-08-23
- Completion
- 2018-08-23
- First posted
- 2018-07-24
- Last updated
- 2018-12-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03596632. Inclusion in this directory is not an endorsement.